Skip to content
HowShorted

Oric Pharmaceuticals, Inc. short interest in 2023

In 2023, Oric Pharmaceuticals, Inc.'s disclosed short interest ran from 9.70% of shares outstanding on 13 Jan 2023 to 15.95% on 29 Dec 2023, a change of +6.25 percentage points. The year's high was 16.36% on 30 Nov 2023 and its low 9.07% on 15 Mar 2023, averaging 11.89% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 42.01 days on 15 May 2023. Full history: Oric Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Oric Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
9.70% (13 Jan 2023)
End of year
15.95% (29 Dec 2023)
Change
+6.25 pp
High
16.36% (30 Nov 2023)
Low
9.07% (15 Mar 2023)
Average
11.89%
Highest days to cover
42.01 (15 May 2023)
SEC filings marked
9

Every report in 2023

Oric Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20239.70%7.24results (8-K)
31 Jan 202310.80%15.13
15 Feb 202310.48%18.00
28 Feb 202310.48%27.72
15 Mar 20239.07%36.86
31 Mar 20239.24%15.2710-K filed, results (8-K)
14 Apr 20239.41%28.22
28 Apr 20239.40%27.95
15 May 20239.49%42.0110-Q filed, results (8-K)
31 May 20239.57%40.26
15 Jun 202311.02%14.08
30 Jun 202313.17%4.64
14 Jul 202313.18%24.00
31 Jul 202312.91%18.99
15 Aug 202310.81%21.7810-Q filed, results (8-K)
31 Aug 202311.18%27.19
15 Sep 202311.43%21.48
29 Sep 202312.59%12.95
13 Oct 202313.20%13.08
31 Oct 202313.99%14.29
15 Nov 202316.08%18.6210-Q filed, results (8-K)
30 Nov 202316.36%28.95
15 Dec 202315.89%18.59
29 Dec 202315.95%34.08

See also: Oric Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.